KR20220140781A - 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제 - Google Patents

고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제 Download PDF

Info

Publication number
KR20220140781A
KR20220140781A KR1020227031209A KR20227031209A KR20220140781A KR 20220140781 A KR20220140781 A KR 20220140781A KR 1020227031209 A KR1020227031209 A KR 1020227031209A KR 20227031209 A KR20227031209 A KR 20227031209A KR 20220140781 A KR20220140781 A KR 20220140781A
Authority
KR
South Korea
Prior art keywords
fgfr
fgfr3
patient
inhibitor
erdafitinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227031209A
Other languages
English (en)
Korean (ko)
Inventor
매니쉬 몽가
마하디 알리 바이그
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20220140781A publication Critical patent/KR20220140781A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227031209A 2020-02-12 2021-02-11 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제 Pending KR20220140781A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US62/975,547 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US63/018,914 2020-05-01
US202063118475P 2020-11-25 2020-11-25
US63/118,475 2020-11-25
PCT/EP2021/053385 WO2021160764A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
KR20220140781A true KR20220140781A (ko) 2022-10-18

Family

ID=74666675

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227031209A Pending KR20220140781A (ko) 2020-02-12 2021-02-11 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제

Country Status (14)

Country Link
US (1) US20230110113A1 (https=)
EP (1) EP4103185A1 (https=)
JP (1) JP2023513704A (https=)
KR (1) KR20220140781A (https=)
CN (1) CN115103678A (https=)
AU (1) AU2021220285A1 (https=)
BR (1) BR112022015827A2 (https=)
CA (1) CA3162962A1 (https=)
IL (1) IL295514A (https=)
JO (1) JOP20220182A1 (https=)
MX (1) MX2022009905A (https=)
PH (1) PH12022552093A1 (https=)
TW (1) TW202143970A (https=)
WO (1) WO2021160764A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312063A (en) * 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
KR20240145513A (ko) * 2022-02-18 2024-10-07 타리스 바이오메디컬 엘엘씨 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템
KR20250143348A (ko) * 2023-02-13 2025-10-01 타리스 바이오메디컬 엘엘씨 방광암 치료에 사용하기 위한 방광내 투여용 에르다피티닙
EP4665341A1 (en) * 2023-02-13 2025-12-24 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
CN120731077A (zh) * 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
KR102470456B1 (ko) * 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése
TWI798199B (zh) * 2017-02-06 2023-04-11 比利時商健生藥品公司 癌症治療

Also Published As

Publication number Publication date
AU2021220285A1 (en) 2022-10-06
IL295514A (en) 2022-10-01
US20230110113A1 (en) 2023-04-13
TW202143970A (zh) 2021-12-01
JOP20220182A1 (ar) 2023-01-30
BR112022015827A2 (pt) 2022-10-04
CA3162962A1 (en) 2021-08-19
JP2023513704A (ja) 2023-04-03
WO2021160764A1 (en) 2021-08-19
EP4103185A1 (en) 2022-12-21
CN115103678A (zh) 2022-09-23
PH12022552093A1 (en) 2023-11-29
MX2022009905A (es) 2022-08-25

Similar Documents

Publication Publication Date Title
KR20220140781A (ko) 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
KR20210143878A (ko) 요로상피세포암종의 치료를 위한 fgfr 티로신 키나제 저해제
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
HK40081735A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
EP4665341A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000